Hostname: page-component-7c8c6479df-r7xzm Total loading time: 0 Render date: 2024-03-28T16:02:51.769Z Has data issue: false hasContentIssue false

The development of leukaemia in a patient receiving clozapine

Published online by Cambridge University Press:  02 January 2018

Imad M. Ali
Affiliation:
Bro Morgannwg NHS Trust, Coity Clinic, Princess of Wales Hospital, Coity Road, Bridgend CF31 1RQ
Toyin Adeyemo
Affiliation:
Bro Morgannwg NHS Trust, Coity Clinic, Princess of Wales Hospital, Coity Road, Bridgend CF31 1RQ
Rights & Permissions [Opens in a new window]

Abstract

Type
The Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2000, The Royal College of Psychiatrists

Sir: Patients receiving clozapine must be registered with the Clozaril Patient Monitoring Service (CPMS) for regular haematological monitoring to reduce the risk of agranulocytosis. We report the case of a 55-year-old patient with a 26-year history of paranoid schizophrenia, whose illness had been well-controlled for 4 years with 400 mg clozapine. Unfortunately, the development of chronic lymphocytic leukaemia necessitated withdrawal of clozapine, resulting in a florid relapse of schizophrenia.

A review of the previous test results revealed they were consistently reported as ‘green’ by the CPMS, despite a gradually rising total white cell count from 8 to 20 over the previous 3 years. The total white cell count ranged from 11 to 15 until a recent increase to 20. As this patient's schizophrenia was well controlled on clozapine, this was continued until diagnosis of chronic lymphocytic leukaemia was made at routine review. A subsequent haematological opinion has not suggested any treatment.

There are isolated reports of leukaemia associated with clozapine, but the observed rate is probably the same as the background incidence, with little evidence of a causal relationship. Other haematological abnormalities have been reported in patients taking clozapine, including leucocytosis, lymphopenia, eosinophilia, thrombocytopenia and anaemia (Reference Mendelowitz, Stanton and GersonMendelowitz et al, 1995; Reference Barbui, Campomori and BonatiBarbui et al, 1997). Clinicians should be aware that the CPMS only monitors for a low total white cell and neutrophil count. They should therefore remain alert to the possibility of less common haematological disorders and should not rely entirely on a ‘green’ result from the CPMS.

References

Barbui, C., Campomori, A. & Bonati, M. (1997) Clozapine and blood dyscrasias different from agranulocytosis. Canadian Journal of Psychiatry – revue canadienne de psychiatrie, 42, 981982.CrossRefGoogle ScholarPubMed
Mendelowitz, A. J., Stanton, L., Gerson, L., et al (1995) Clozapine induced agranulocytosis. CNS Drugs, 4, 412421.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.